Michael A Burg

Title: Michael A. Burg: Innovator in Angiogenic Vasculature Targeting

Introduction

Michael A. Burg is a notable inventor based in San Diego, California. He has made significant contributions to the field of biomedical research, particularly in the development of angiogenic vasculature homing molecules. His work focuses on innovative methods to target and inhibit angiogenesis in tumors, which is crucial for advancing cancer treatment.

Latest Patents

Michael A. Burg holds a patent for "NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods." This invention provides angiogenic vasculature homing molecules that bind to NG2/HM proteoglycan. The patent includes peptides with specific amino acid sequences, such as TAASGVRSMH and LTLRWVGLMS. Additionally, it describes conjugates that link these homing molecules to various therapeutic agents, enhancing their effectiveness in targeting tumors.

Career Highlights

Michael A. Burg is affiliated with the Burnham Institute, where he conducts research and develops innovative solutions in the field of cancer biology. His work has the potential to transform how angiogenesis is targeted in cancer therapies, providing new avenues for treatment.

Collaborations

Michael collaborates with esteemed colleagues, including Renata Pasqualini and Wadih Arap. Their combined expertise contributes to the advancement of research in angiogenesis and cancer treatment.

Conclusion

Michael A. Burg is a pioneering inventor whose work in angiogenic vasculature targeting holds promise for improving cancer therapies. His innovative approaches and collaborations continue to push the boundaries of biomedical research.